Study of the Role of Innate Lymphoid Cells and Natural Killer Cells in Immune Activation of Vitiligo - INNATE Vitiligo

Completed

• Conditions: Vitiligo
• Interventions: Other: blood and skin samples

• Registration Number: NCT03859518
• Lead Sponsor: Centre Hospitalier Universitaire de Nice

Brief Summary

The cohort included only major patients with non-segmental vitiligo and no other autoimmune or inflammatory associated diseases (except thyroiditis). Control subjects should have no autoimmune or inflammatory diseases. Patients and controls should not take treatment with corticosteroids or other potentially immunomodulatory therapies. Patients and controls are recruited in the Dermatology Department of the University Hospital of Nice and the Hospital of Fréjus. The investigators have already initiated the collection of tissues and blood from patients and control subjects and we have succeeded in isolating ILCs and NKs from a blood volume of 50ml. We were able to sort the ILC subpopulations. Early data suggest an increase in Natural Killer (NK) and Innate Lymphoïdes Cells 1 (ILC1) in the blood of vitiligo patients compared to control subjects. The investigators also managed to extract the melanocytes from the skin biopsies of the first patients and control subjects.

Detailed Description

The investigators want study the presence and type of ILC and NK in the blood and skin of vitiligo patients compared to control subjects.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2016-07
• Primary Completion: 2016-07
• Status Verified: 2019-01
• Study First Submitted: 2019-02-26
• Study First Submitted QC: 2019-02-27
• Study First Posted: 2019-03-01
• Study Completion: 2019-12
• Last Update Submitted: 2019-12-06
• Last Update Posted: 2019-12-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

vitiligo subjects :

• patients in the cohort with non-segmental vitiligo
• without other autoimmune or inflammatory diseases associated

control subjects :

• subject without autoimmune or inflammatory disease

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
patients with Vitiligo	blood and skin samples	-
control	blood and skin samples	-

Primary Outcome Measures

Name	Time	Method
study the presence and type of ILC and NK in the blood and skin	1 day	Compare vitiligo patients to control subjects.
study the presence and type of ILC and NK in the skin	1 day	Compare vitiligo patients to control subjects.

Trial Locations

Locations (1)

CH de Frejus; 🇫🇷 Fréjus, France